

# Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on Sunday, the 30 April 2023 at 3.00 p.m. at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 has approved the Un-audited 3<sup>rd</sup> quarter Financial Statements of the Company for the period ended 31 March 2023 and has decided, declared and recommended the following price sensitive information accordingly:

The Board of Directors of the Company declared the following financial information:

## 1) Financial Information:

- a. Earning Per Share (EPS) : Tk. 2.57
- b. Net Asset Value Per Share (NAVPS) : Tk. 26.68
- c. Net Operating Cash Flow Per Share (NOCFPS) : Tk. 2.33

## 2) Comparative Statement of Financial Information:

Particulars	Jul'22-Mar'23	Jul'21-Mar'22	Jan'23-Mar'23	Jan'22-Mar'22
Earning Per Share (EPS)	Tk. 2.57	Tk. 3.58	Tk. (0.04)	Tk. .99
Net Asset Value Per Share (NAVPS)	Tk. 26.68	Tk. 25.26	Tk. 26.68	Tk. 25.26
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 2.33	Tk. 1.16	-	-

Date : 30.04.2023

By order of the Board of Directors



Beacon Business Centre  
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223

A handwritten signature in black ink, appearing to read 'Khalilur Rahman', is written over a horizontal line.

**Khalilur Rahman FCS**  
Company Secretary